Cancer drug causes patient to lose fingerprints
27 May, 2009 by Staff WritersA man travelling to the United States was detained by immigration officials for four hours before they allowed him to enter because one of his cancer drugs caused his fingerprints to disappear.
Australian biotech market today 22.05.09
22 May, 2009 by Staff WritersCSL, ResMed, Cochlear, Ramsay, Ansell
Hot Arabidopsis and its triplet trouble
14 May, 2009 by Kate McDonaldA massive triplet repeat expansion found in a wild strain of Arabidopsis thaliana could prove a very useful, and genetically tractable, model to study aspects of trinucleotide repeat disorders.
Starpharma scores another multinational
11 May, 2009 by Kate McDonaldStarpharma signs deal with Eli Lilly’s animal health division
Eye on emu for BioProspect
11 May, 2009 by Kate McDonaldTermite foe BioProspect eyes off emu oil product range
Flummoxing flukes with PCR test
07 May, 2009 by Kate McDonaldAustralian researchers have developed a highly specific PCR-based technique to distinguish between species of intestinal and liver flukes, which should help in epidemiological surveys of these widespread and often dangerous parasites.
Australian biotech market today 06.05.09
06 May, 2009 by Staff WritersCochlear, CSL, ResMed, Pharmaxis, Novogen, SciGen
Biotech profile: Novogen
05 May, 2009 by Kate McDonaldNovogen has developed a technology platform based on synthetic isoflavones that promises compounds which can kill cancer cells without harming healthy cells.
Australian biotech market today 05.05.09
05 May, 2009 by Kate McDonaldCOH, CSL, RMD, Pharmaxis, Sonic Healthcare, Avexa, Cellestis
Pharmaxis progresses Bronchitol
05 May, 2009 by Kate McDonaldPositive data from Pharmaxis’ Phase III trial in cystic fibrosis
Profile: Implicit Biosciences
29 April, 2009 by Kate McDonaldBrisbane biotech Implicit Bioscience has developed a business model unusual in Australia: it aims to return money to investors.
Biotech profile: Hexima
28 April, 2009 by Kate McDonaldMelbourne agbiotech Hexima has been making waves with its fungal and insect-resistance technology and a tasty deal with DuPont.
Australian biotech market today 28.04.09
28 April, 2009 by Kate McDonaldBiota, CSL, Hexima, Alchemia, Mesoblast
Mesoblast fuses Phase II
28 April, 2009 by Kate McDonaldMesoblast approved for Phase II trail for cervical spine fusion
Prima applies for IND
28 April, 2009 by Kate McDonaldPrima BioMed applies for IND for CVac, raises cash
